Mezgebe Berhe

Also affiliated with Infectious Disease Consultants

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial”.

Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial

The Lancet Respiratory Medicine(2022)10.1016/s2213-2600(22)00215-6

N/A

4.5DataRank · unranked

128 citations

Adit A. Ginde, Roger Paredes, Thomas A. Murray, Nicole Engen, Greg Grandits +95 more

Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial

The Lancet Respiratory Medicine(2022)10.1016/s2213-2600(22)00088-1

N/A

3.0DataRank · unranked

128 citations

Kay M Tomashek, Thomas F. Patterson, Carlos A. Gómez, Vincent C. Marconi, Mamta K. Jain +95 more

Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks

Open Forum Infectious Diseases(2023)10.1093/ofid/ofad101

N/A

0DataRank · unranked

24 citations

Mezgebe Berhe, Tulika Singh, Roberto Ortiz, Anson K Wurapa, Moti Ramgopal +12 more